Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

HCW starts Akouos at buy; PT $25

H.C. Wainwright launched coverage of Akouos (NASDAQ:AKUS) with a “buy” rating and $25 price target. The stock closed at $15.03 on April 26. Akouos is a precision genetic medicine company focused primarily on the...

April 27, 2021

Markets

Stifel ups Xenon Pharma PT to $31 from $23

Stifel raised its price target for Xenon Pharmaceuticals (NASDAQ:XENE) to $31 from $23, ahead of Phase 2b focal seizure data expected in the third quarter this year. The stock closed at $17.97 on April 23. “From our...

April 26, 2021

Markets

HCW starts Adicet Bio at buy; PT $27

H.C. Wainwright launched coverage of Adicet Bio (NASDAQ:ACET) with a “buy” rating and $27 price target. The stock closed at $13.11 on April 22. Adicet is focused on developing allogeneic gamma-delta T-cell therapies for...

April 23, 2021

Markets

Maxim starts CohBar at buy; PT $3

Maxim Group initiated coverage of CohBar (NASDAQ:CXBR), which is developing a therapeutic platform based on mitochondrial-derived peptides, with a “buy” rating and price target of $3. The stock closed at $1.24 on April...

April 23, 2021

Markets

Maxim ups Cerecor to buy from hold; PT $7

Maxim Group upgraded Cerecor (NASDAQ:CERC) to “buy” from “hold” with a price target of $7, citing an advancing pipeline of assets and the potential for multiple priority review vouchers (PRVs). The stock closed at $2.34...

April 21, 2021

Markets

Cantor starts 89bio at OW; PT $58

Cantor Fitzgerald launched coverage of 89bio (NASDAQ:ETNB) with an “overweight” rating and $58 price target. The stock closed at $25.81 on April 20. 89bio is developing BIO89-100, its injectable FGF21 hormone analog...

April 21, 2021

Markets

Maxim starts Fennec Pharma at buy: PT $12

Maxim Group initiated coverage of Fennec Pharmaceuticals (NASDAQ:FENC) with a “buy” rating and price target of $12. The stock closed at $6.27 on April 16. Fennec is developing PEDMARK, a unique formulation of sodium...

April 19, 2021

Markets

Echelon starts Cognetivity Neurosciences at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF)) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 48.5 cents on April 16...

April 19, 2021

Markets

SVB Leerink starts Lava Therapeutics at OP; PT $26

SVB Leerink launched coverage of Lava Therapeutics N.V. (NASDAQ:LVTX) with an “outperform” rating and $26 price target. The stock closed at $15 on April 16. Lava is at the leading edge of therapeutically targeting the...

April 19, 2021

Markets

Citi transfers coverage of 111 Inc. with $16 PT

Citi Research transferred coverage of 111 Inc. (NASDAQ:YI) to Zoe Bian from Cui Cui, retaining a “buy/high risk” rating and price target of $16. Citi recently raised its price target to $16 from $12. The stock closed at...

April 19, 2021

Markets

BTIG ups TRACON Pharma to buy from neutral with $14 PT

BTIG upgraded TRACON Pharmaceuticals (NASDAQ:TCON) to “buy” from “neutral” with a new price target of $14, citing pivotal trial dosing for the company’s envafolimab and expansion opportunities, which are under...

April 16, 2021

Markets

Canaccord starts Exagen at buy; PT $25

Canaccord Genuity launched coverage of Exagen (NASDAQ:XGN) with a “buy” rating and $25 price target. The stock closed at $16.69 on April 14. Analyst Max Masucci writes that Exagen provides a broad range of tests used to...

April 15, 2021

Markets

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12. Connect is a clinical-stage biotech headquartered in...

April 13, 2021

Markets

BTIG starts Gain Therapeutics at buy; PT 30

BTIG initiated coverage of Gain Therapeutics (NASDAQ:GANX) with a “buy” rating and $30 price target. The stock closed at $13.98 on April 9. Gain is a computational and medicinal chemistry-based biotechnology company...

April 12, 2021

Markets

Echelon pegs DIAGNOS as Q2 “top picks portfolio”

Echelon Capital Markets added DIAGNOS (TSXV:ADK) to its second quarter “top picks portfolio.” Analyst Stefan Quenneville rates the stock as “speculative buy” with a price target of 85 cents. The stock was quoted at 53...

April 8, 2021

Markets

Maxim ups Mesoblast to buy from hold; PT $18

Maxim Group upgraded Mesoblast (NASDAQ:MESO) to “buy” from “hold” with a price target of $18, citing the totality of the company’s cell therapy data, which are “quite good.” The stock closed at $8.45 on April 6...

April 7, 2021

Markets

Analysts start Prometheus Biosciences at OP and buy

Analysts for Stifel and SVB Leerink initiated coverage of Prometheus Biosciences (NASDAQ:RXDX) with “outperform” and “buy” ratings, respectively, and price targets of $25 and $34, respectively. The stock closed at $19...

April 6, 2021

Markets

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

April 6, 2021

Markets

Raymond James ups Perimeter Medical Imaging PT to $6.50 (Canadian) from $3

Raymond James raised its price target for Perimeter Medical Imaging (TSXV:PINK) to $6.50 (Canadian) from $3, citing a deeper look at the artificial intelligence-enabled application of the company’s Optical...

April 5, 2021

Markets

HCW downgrades BeyondSpring to neutral from buy; removes PT

H.C. Wainwright downgraded BeyondSpring (NASDAQ:BYSI) to “neutral” from “buy” and removed its price target, citing a change to the company’s risk profile. The stock closed at $10.80 on April 1. On March 31, BeyondSpring...

April 5, 2021

Markets

AGP cuts EyeGate Pharma PT to $10.25 from $16.75

Alliance Global Partners reduced its price target for EyeGate Pharmaceuticals (NASDAQ:EYEG) to $10.25 from $16.75, citing a possible plan to sell additional common shares in the first half of this year in order to...

March 31, 2021

Markets

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

March 31, 2021

Subscribe